Literature DB >> 11969312

Effects of image resolution on autoradiographic measurements of posterior cingulate activity in PDAPP mice: implications for functional brain imaging studies of transgenic mouse models of Alzheimer's Disease.

J Valla1, K Chen, J D Berndt, F Gonzalez-Lima, S R Cherry, D Games, E M Reiman.   

Abstract

Fluorodeoxyglucosepositron emission tomography (PET) studies find that persons with Alzheimer's disease have preferential reductions in posterior cingulate activity. Using fluorodeoxyglucose autoradiography, we found that transgenic mice overexpressing a mutant form of the human amyloid precursor protein have preferentially reduced activity in the same region, providing a potential brain imaging indicator of Alzheimer's disease in these animals. In this study, we considered the feasibility of using in vivo imaging techniques, such as PET, to detect this reduction despite their limitations in spatial resolution. Autoradiographic measurements of posterior cingulate activity were remeasured in the previously studied PDAPP transgenic and littermate control mice after the images were filtered to lower spatial resolutions. We continued to detect significantly lower cingulate activity in the transgenic mice when the images were blurred to 0.50 mm, failed to detect significantly abnormal activity when the images were blurred to 0.75 mm, and, indeed, found significantly higher activity when the images were blurred to 1.0 mm. Reversal in direction of the abnormality appears attributable to a previously observed truncation in the corpus callosum in PDAPP mice. With the possible exception of future in vivo imaging techniques that have a spatial resolution greater than or equal to 0.50 mm and high sensitivity, noninvasive functional brain imaging techniques like PET may not be suitable for detecting declines in regional activity in PDAPP mice. It remains possible that these imaging techniques will prove useful in transgenic mouse lines that do not exhibit the same morphological abnormalities in neighboring white matter regions. 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11969312     DOI: 10.1006/nimg.2002.1080

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  7 in total

1.  Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice.

Authors:  Jon Valla; Lonnie Schneider; Eric M Reiman
Journal:  Brain Res       Date:  2006-08-30       Impact factor: 3.252

2.  Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models.

Authors:  Rachel M Nicholson; Yael Kusne; Lee A Nowak; Frank M LaFerla; Eric M Reiman; Jon Valla
Journal:  Brain Res       Date:  2010-08-06       Impact factor: 3.252

3.  Methylene blue prevents neurodegeneration caused by rotenone in the retina.

Authors:  Xian Zhang; Julio C Rojas; F Gonzalez-Lima
Journal:  Neurotox Res       Date:  2006-01       Impact factor: 3.911

4.  Alzheimer's disease biomarkers in animal models: closing the translational gap.

Authors:  Jonathan J Sabbagh; Jefferson W Kinney; Jeffrey L Cummings
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

Review 5.  Animal models of neurodegenerative disease: insights from in vivo imaging studies.

Authors:  Elissa M Strome; Doris J Doudet
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.484

Review 6.  A review of β-amyloid neuroimaging in Alzheimer's disease.

Authors:  Paul A Adlard; Bob A Tran; David I Finkelstein; Patricia M Desmond; Leigh A Johnston; Ashley I Bush; Gary F Egan
Journal:  Front Neurosci       Date:  2014-10-31       Impact factor: 4.677

7.  In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 mice.

Authors:  Ann-Marie Waldron; Cindy Wintmolders; Astrid Bottelbergs; Jonathan B Kelley; Mark E Schmidt; Sigrid Stroobants; Xavier Langlois; Steven Staelens
Journal:  Alzheimers Res Ther       Date:  2015-12-15       Impact factor: 6.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.